Progress toward gene therapy of Duchenne muscular dystrophy

Dennis Hartigan-O'Connor, Jeffrey S. Chamberlain

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Duchenne muscular dystrophy (DMD) is a common lethal disease for which no effective treatment is available. The lethal consequences of DMD are caused by absence of a structural protein, called dystrophin, from skeletal and cardiac muscle cells. The usefulness of gene replacement as therapy for this disease has been established in transgenic mouse models. Unfortunately, progress toward therapy for human patients has been limited by the characteristics of currently available viral vectors and by lack of a suitable technique for delivery of such vectors to a large mass of muscle cells. Successful gene therapy of DMD wisll require a vector that can carry most of the dystrophin coding sequence, that can be cheaply produced in large quantities, that can be delivered to a large mass of muscle cells, and that provides stable expression of dystrophin after delivery. We and others have worked to develop such a vector through modification of adenoviruses (Ad). Here we review the characteristics of conventional Ad vectors and new helper- dependent, or gutted, Ad vectors. Gutted Ad vectors contain cis-acting DNA sequences necessary for viral replication and packaging, but are deleted, or gutted, for all viral coding sequences. We found that gutted vectors efficiently delivered full-length dystrophin to the skeletal muscles of dystrophic (mdx) mice. Dystrophic muscles injected with these vectors expressed dystrophin for at least four months post-injection, which was the longest time point tested. These data suggest that gutted vectors will allow delivery and long-term expression of dystrophin.

Original languageEnglish (US)
Pages (from-to)323-332
Number of pages10
JournalSeminars in Neurology
Volume19
Issue number3
StatePublished - 1999
Externally publishedYes

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
Genetic Therapy
Adenoviridae
Muscle Cells
Skeletal Muscle
Inbred mdx Mouse
Virus Assembly
Cardiac Myocytes
Transgenic Mice
Therapeutics
Muscles
Injections
Genes
Proteins

Keywords

  • Adenovirus
  • Duchenne
  • Dystrophin
  • Gene therapy
  • Gutless
  • Gutted
  • Helper- dependent
  • Vector

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Progress toward gene therapy of Duchenne muscular dystrophy. / Hartigan-O'Connor, Dennis; Chamberlain, Jeffrey S.

In: Seminars in Neurology, Vol. 19, No. 3, 1999, p. 323-332.

Research output: Contribution to journalArticle

Hartigan-O'Connor, Dennis ; Chamberlain, Jeffrey S. / Progress toward gene therapy of Duchenne muscular dystrophy. In: Seminars in Neurology. 1999 ; Vol. 19, No. 3. pp. 323-332.
@article{9d8967a7d4994f00a8aa5eaa426ac321,
title = "Progress toward gene therapy of Duchenne muscular dystrophy",
abstract = "Duchenne muscular dystrophy (DMD) is a common lethal disease for which no effective treatment is available. The lethal consequences of DMD are caused by absence of a structural protein, called dystrophin, from skeletal and cardiac muscle cells. The usefulness of gene replacement as therapy for this disease has been established in transgenic mouse models. Unfortunately, progress toward therapy for human patients has been limited by the characteristics of currently available viral vectors and by lack of a suitable technique for delivery of such vectors to a large mass of muscle cells. Successful gene therapy of DMD wisll require a vector that can carry most of the dystrophin coding sequence, that can be cheaply produced in large quantities, that can be delivered to a large mass of muscle cells, and that provides stable expression of dystrophin after delivery. We and others have worked to develop such a vector through modification of adenoviruses (Ad). Here we review the characteristics of conventional Ad vectors and new helper- dependent, or gutted, Ad vectors. Gutted Ad vectors contain cis-acting DNA sequences necessary for viral replication and packaging, but are deleted, or gutted, for all viral coding sequences. We found that gutted vectors efficiently delivered full-length dystrophin to the skeletal muscles of dystrophic (mdx) mice. Dystrophic muscles injected with these vectors expressed dystrophin for at least four months post-injection, which was the longest time point tested. These data suggest that gutted vectors will allow delivery and long-term expression of dystrophin.",
keywords = "Adenovirus, Duchenne, Dystrophin, Gene therapy, Gutless, Gutted, Helper- dependent, Vector",
author = "Dennis Hartigan-O'Connor and Chamberlain, {Jeffrey S.}",
year = "1999",
language = "English (US)",
volume = "19",
pages = "323--332",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Progress toward gene therapy of Duchenne muscular dystrophy

AU - Hartigan-O'Connor, Dennis

AU - Chamberlain, Jeffrey S.

PY - 1999

Y1 - 1999

N2 - Duchenne muscular dystrophy (DMD) is a common lethal disease for which no effective treatment is available. The lethal consequences of DMD are caused by absence of a structural protein, called dystrophin, from skeletal and cardiac muscle cells. The usefulness of gene replacement as therapy for this disease has been established in transgenic mouse models. Unfortunately, progress toward therapy for human patients has been limited by the characteristics of currently available viral vectors and by lack of a suitable technique for delivery of such vectors to a large mass of muscle cells. Successful gene therapy of DMD wisll require a vector that can carry most of the dystrophin coding sequence, that can be cheaply produced in large quantities, that can be delivered to a large mass of muscle cells, and that provides stable expression of dystrophin after delivery. We and others have worked to develop such a vector through modification of adenoviruses (Ad). Here we review the characteristics of conventional Ad vectors and new helper- dependent, or gutted, Ad vectors. Gutted Ad vectors contain cis-acting DNA sequences necessary for viral replication and packaging, but are deleted, or gutted, for all viral coding sequences. We found that gutted vectors efficiently delivered full-length dystrophin to the skeletal muscles of dystrophic (mdx) mice. Dystrophic muscles injected with these vectors expressed dystrophin for at least four months post-injection, which was the longest time point tested. These data suggest that gutted vectors will allow delivery and long-term expression of dystrophin.

AB - Duchenne muscular dystrophy (DMD) is a common lethal disease for which no effective treatment is available. The lethal consequences of DMD are caused by absence of a structural protein, called dystrophin, from skeletal and cardiac muscle cells. The usefulness of gene replacement as therapy for this disease has been established in transgenic mouse models. Unfortunately, progress toward therapy for human patients has been limited by the characteristics of currently available viral vectors and by lack of a suitable technique for delivery of such vectors to a large mass of muscle cells. Successful gene therapy of DMD wisll require a vector that can carry most of the dystrophin coding sequence, that can be cheaply produced in large quantities, that can be delivered to a large mass of muscle cells, and that provides stable expression of dystrophin after delivery. We and others have worked to develop such a vector through modification of adenoviruses (Ad). Here we review the characteristics of conventional Ad vectors and new helper- dependent, or gutted, Ad vectors. Gutted Ad vectors contain cis-acting DNA sequences necessary for viral replication and packaging, but are deleted, or gutted, for all viral coding sequences. We found that gutted vectors efficiently delivered full-length dystrophin to the skeletal muscles of dystrophic (mdx) mice. Dystrophic muscles injected with these vectors expressed dystrophin for at least four months post-injection, which was the longest time point tested. These data suggest that gutted vectors will allow delivery and long-term expression of dystrophin.

KW - Adenovirus

KW - Duchenne

KW - Dystrophin

KW - Gene therapy

KW - Gutless

KW - Gutted

KW - Helper- dependent

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=0032729844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032729844&partnerID=8YFLogxK

M3 - Article

C2 - 12194388

AN - SCOPUS:0032729844

VL - 19

SP - 323

EP - 332

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 3

ER -